Revvity Launches CE-IVDR T1D Early Detection Solution
WALTHAM, Mass. — September 24, 2026 Revvity, Inc. announced the launch of the GSP® T1D 3plex kit, a fully...
Sanofi
Advertisement
Sanofi and Cheplapharm Form Strategic Mature Medicines Partnership
PARIS, France — September 14, 2026 Sanofi and Cheplapharm announced plans to create a new strategic partnership under which...
Nurix and Sanofi Advance Oral STAT6 Degrader into Phase 1 Clinical Development
BRISBANE, Calif., August 4, 2026 Nurix Therapeutics, Inc. announced it has earned a $10 million development milestone payment after...
Sanofi Ends Amlitelimab Development for Atopic Dermatitis
PARIS, France, July 24, 2026 Sanofi announced that it has discontinued the clinical development of amlitelimab for moderate-to-severe atopic...
Aqemia Broadens AI Drug Discovery Research with Sanofi
PARIS & LONDON, July 17, 2026 Aqemia, the biotechnology company pioneering physics-based generative artificial intelligence (AI) for drug discovery,...
Advertisements
Sanofi Secures FDA Nod for Sarclisa Escena
PARIS, July 10, 2026 Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Sarclisa Escena® (isatuximab-irfc)...
Sanofi Wins Japan Approval for Wayrilz in Rare Blood Disease
PARIS, June 23, 2026 Sanofi has secured an important regulatory milestone after Japan’s Ministry of Health, Labour and Welfare...
Sanofi Wins Japan Approval for Sarclisa SC in Myeloma
PARIS | June 19, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the...
Sanofi’s Tzield Gains FDA Approval in Stage 3 Type 1 Diabetes
PARIS, France, June 13, 2026 Sanofi has achieved a major breakthrough in diabetes care after the U.S. Food and...
Sanofi Ends Phase 3 MOBILIZE Trial of Riliprubart in CIDP
PARIS, France, June 10, 2026 Sanofi announced that it will discontinue the Phase 3 MOBILIZE study evaluating riliprubart in...
Advertisement
